Jennifer Good is co-founder and CEO of New Haven-based Trevi Therapeutics and has more than 25 years of experience in the biotechnology industry. She has led companies through multiple stages of growth, including clinical development, regulatory approval and public market financing.
Good has helped secure approximately $1 billion in funding through angel investments, initial public offerings and follow-on equity offerings. Prior to Trevi, she helped lead Penwest Pharmaceuticals through Food and Drug Administration approval and its eventual sale.
Over the past year, Trevi reported positive clinical trial results for its drug candidate targeting idiopathic pulmonary fibrosis-related chronic cough and refractory chronic cough, with the company saying the therapy demonstrated statistically significant results and a favorable safety profile.
Trevi also raised approximately $300 million to advance its development programs into late-stage trials. Good said the company’s biggest challenge over the next two years will be executing large global clinical trials involving more than 600 patients across multiple countries.
If you could change one thing in the healthcare industry, what would it be?
I believe it is vital to recognize the U.S. ecosystem as the primary engine for global medical innovation. We should maintain an environment that supports the immense investment required for high-risk research. Protecting our leadership in biotech is a strategic priority, ensuring patients everywhere have access to tomorrow’s cures.